MCID: MLG002
MIFTS: 46

Malignant Peritoneal Mesothelioma malady

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Malignant Peritoneal Mesothelioma

Aliases & Descriptions for Malignant Peritoneal Mesothelioma:

Name: Malignant Peritoneal Mesothelioma 56
Diffuse Malignant Peritoneal Mesothelioma 56
Primary Malignant Peritoneal Mesothelioma 56
Malignant Mesothelioma of Peritoneum 69

Characteristics:

Orphanet epidemiological data:

56
malignant peritoneal mesothelioma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (France),1-9/100000 (Europe),1-9/1000000 (Italy); Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Orphanet 56 ORPHA168811
UMLS via Orphanet 70 C0346109
ICD10 via Orphanet 34 C45.1

Summaries for Malignant Peritoneal Mesothelioma

MalaCards based summary : Malignant Peritoneal Mesothelioma, also known as diffuse malignant peritoneal mesothelioma, is related to peritoneal mesothelioma and peritonitis, and has symptoms including ascites, weight loss and abnormality of coagulation. An important gene associated with Malignant Peritoneal Mesothelioma is VIM (Vimentin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Pathways in cancer. The drugs Doxorubicin and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include colon, lung and lymph node, and related phenotypes are Decreased cell migration and Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance

Related Diseases for Malignant Peritoneal Mesothelioma

Diseases in the Peritoneal Mesothelioma family:

Benign Peritoneal Mesothelioma Malignant Peritoneal Mesothelioma

Diseases related to Malignant Peritoneal Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 164)
id Related Disease Score Top Affiliating Genes
1 peritoneal mesothelioma 11.6
2 peritonitis 10.9
3 13q12.3 microdeletion syndrome 10.2 CDKN2A VIM
4 myoma 10.2 MUC1 VIM
5 spleen angiosarcoma 10.2 MUC1 VIM
6 marfanoid hypermobility syndrome 10.2 MUC1 VIM
7 autosomal recessive stickler syndrome 10.2 MUC1 VIM
8 biliary papillomatosis 10.2 MUC1 VIM
9 microinvasive cervical squamous cell carcinoma 10.2 MUC1 VIM
10 endometrial stromal sarcoma 10.2 MUC1 VIM
11 tanycytic ependymoma 10.2 MUC1 VIM
12 aml with myelodysplasia-related features 10.2 CDKN2A VIM
13 subglottis verrucous carcinoma 10.2 MUC1 VIM
14 conjunctival cancer 10.2 MUC1 VIM
15 clear cell ependymoma 10.2 MUC1 VIM
16 behcet's syndrome arthropathy 10.2 MUC1 VIM
17 sternum cancer 10.2 MUC1 VIM
18 testicular granulosa cell tumor 10.2 MUC1 VIM
19 petrous apex meningioma 10.2 MUC1 VIM
20 vulvar angiokeratoma 10.2 MUC1 VIM
21 vulvar squamous papilloma 10.2 MUC1 VIM
22 lymphangiosarcoma 10.2 MUC1 VIM
23 progeria 10.2 MUC1 VIM
24 coronary stenosis 10.2 MUC1 VIM
25 spastic ataxia 5 10.2 CDKN2A VIM
26 sebaceous adenoma 10.2 MUC1 VIM
27 anal gland neoplasm 10.2 MUC1 VIM
28 cauda equina intradural extramedullary astrocytoma 10.2 MUC1 VIM
29 cervical lymphoepithelioma-like carcinoma 10.2 EGFR MUC1
30 gestational trophoblastic neoplasm 10.2 MUC1 VIM
31 appendix mucinous cystadenocarcinoma 10.2 MUC1 VIM
32 mesenchymoma 10.2 MUC1 VIM
33 urethral villous adenoma 10.2 CDKN2A EGFR
34 omodysplasia 2 10.2 MUC1 VIM
35 subependymal glioma 10.2 MUC1 VIM
36 congenital muscular dystrophy with hyperlaxity 10.2 MUC1 VIM
37 ossifying fibromyxoid tumor 10.2 CDKN2A VIM
38 lethal congenital contracture syndrome 10.2 EGFR MUC1
39 differentiating neuroblastoma 10.2 MUC1 VIM
40 precursor t-lymphoblastic lymphoma/leukemia 10.2 EGFR MUC1
41 his bundle tachycardia 10.2 EGFR VIM
42 lung benign neoplasm 10.2 MUC1 VIM
43 ovarian insufficiency due to fsh resistance 10.2 MUC1 VIM
44 gastrointestinal system cancer 10.2 MUC1 VIM
45 diarrhea, chronic, with villous atrophy 10.2 MUC1 VIM
46 tricuspid valve prolapse 10.2 CDKN2A EGFR
47 childhood brain germinoma 10.2 MUC1 VIM
48 intermediate malignant teratoma 10.2 CDKN2A EGFR
49 desmoid tumor 10.2 MUC1 VIM
50 chronic monocytic leukemia 10.2 CDKN2A EGFR

Graphical network of the top 20 diseases related to Malignant Peritoneal Mesothelioma:



Diseases related to Malignant Peritoneal Mesothelioma

Symptoms & Phenotypes for Malignant Peritoneal Mesothelioma

Human phenotypes related to Malignant Peritoneal Mesothelioma:

56 32 (show all 10)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ascites 56 32 Very frequent (99-80%) HP:0001541
2 weight loss 56 32 Frequent (79-30%) HP:0001824
3 abnormality of coagulation 56 32 Occasional (29-5%) HP:0001928
4 abdominal pain 56 32 Very frequent (99-80%) HP:0002027
5 dyspnea 56 32 Occasional (29-5%) HP:0002094
6 peritonitis 56 32 Very frequent (99-80%) HP:0002586
7 ileus 56 32 Occasional (29-5%) HP:0002595
8 neoplasm 56 32 Very frequent (99-80%) HP:0002664
9 abdominal distention 56 32 Very frequent (99-80%) HP:0003270
10 edema of the lower limbs 56 32 Occasional (29-5%) HP:0010741

UMLS symptoms related to Malignant Peritoneal Mesothelioma:


abdominal pain

GenomeRNAi Phenotypes related to Malignant Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.26 EGFR MUC1 NF2 VIM
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 8.8 EGFR MUC1 VIM

MGI Mouse Phenotypes related to Malignant Peritoneal Mesothelioma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.35 BIRC5 CDKN2A EGFR NF2 VIM
2 respiratory system MP:0005388 8.92 VIM CDKN2A EGFR NF2

Drugs & Therapeutics for Malignant Peritoneal Mesothelioma

Drugs for Malignant Peritoneal Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Doxil Approved June 1999 Phase 3,Phase 2 31703
4 Ranpirnase Investigational Phase 3 196488-72-9
5 Topoisomerase Inhibitors Phase 3,Phase 2
6 Anti-Bacterial Agents Phase 3,Phase 2
7 Antibiotics, Antitubercular Phase 3,Phase 2
8 pancreatic polypeptide Phase 3
9 Analgesics Phase 3,Phase 1,Phase 2
10 Adjuvants, Anesthesia Phase 3
11 Narcotics Phase 3
12 Analgesics, Opioid Phase 3
13 Anesthetics Phase 3
14 Anesthetics, General Phase 3
15 Anesthetics, Intravenous Phase 3
16 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
17 Liver Extracts Phase 3,Phase 1
18 Central Nervous System Depressants Phase 3
19 Cola Nutraceutical Phase 3,Phase 2,Phase 1
20
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
21
Gemcitabine Approved Phase 2 95058-81-4 60750
22
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
23
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599, 9887054 43805
24
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
25
Ranitidine Approved Phase 2 66357-59-3, 66357-35-5 3001055
26
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754 657311
27
Diphenhydramine Approved Phase 2 58-73-1, 147-24-0 3100
28
Promethazine Approved Phase 2 60-87-7 4927
29
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
30
Fluorouracil Approved Phase 2 51-21-8 3385
31
Pancrelipase Approved Phase 2 53608-75-6
32
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
33
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
34
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
35
Succinylcholine Approved Phase 1, Phase 2 306-40-1 5314
36
Pembrolizumab Approved Phase 2 1374853-91-4
37
Bevacizumab Approved, Investigational Phase 2 216974-75-3
38
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 40926 439693
39
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
40
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 54575, 6560146 143
41
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
42 interferons Phase 2,Phase 1
43 Alkylating Agents Phase 2,Phase 1
44 Mitomycins Phase 2
45 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
46 Anti-Infective Agents Phase 2,Phase 1
47 Immunosuppressive Agents Phase 2,Phase 1
48 Interferon-gamma Phase 2
49 Antimetabolites Phase 2
50 Antimetabolites, Antineoplastic Phase 2

Interventional clinical trials:

(show all 44)
id Name Status NCT ID Phase
1 ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
3 Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2
4 Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma Unknown status NCT00859469 Phase 2
5 Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer Unknown status NCT00024271 Phase 2
6 Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma Completed NCT01592383 Phase 2
7 Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma Completed NCT00061477 Phase 2
8 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2
9 Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. Completed NCT01721018 Phase 1, Phase 2
10 A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) Recruiting NCT02588131 Phase 2
11 αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies Recruiting NCT02151448 Phase 1, Phase 2
12 Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study Recruiting NCT02588781 Phase 2
13 Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Recruiting NCT02535312 Phase 1, Phase 2
14 Pembrolizumab in Treating Patients With Malignant Mesothelioma Recruiting NCT02399371 Phase 2
15 Atezolizumab and Bevacizumab in Rare Solid Tumors Recruiting NCT03074513 Phase 2
16 Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma Active, not recruiting NCT01843374 Phase 2
17 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Active, not recruiting NCT01160458 Phase 2
18 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Active, not recruiting NCT01362790 Phase 1, Phase 2
19 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Enrolling by invitation NCT02040142 Phase 2
20 Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment Not yet recruiting NCT01627795 Phase 1, Phase 2
21 A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma Withdrawn NCT01353482 Phase 1, Phase 2
22 Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma Completed NCT02141347 Phase 1
23 Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma Completed NCT00402766 Phase 1
24 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma Completed NCT00398138 Phase 1
25 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
26 PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer Completed NCT00055705 Phase 1
27 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
28 Interleukin-12 in Treating Patients With Cancer in the Abdomen Completed NCT00003046 Phase 1
29 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1
30 Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Recruiting NCT02029690 Phase 1
31 Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma Recruiting NCT02798536 Phase 1
32 CAR T Cells in Mesothelin Expressing Cancers Recruiting NCT03054298 Phase 1
33 Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors. Active, not recruiting NCT01439152 Phase 1
34 Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays Completed NCT02834234
35 Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Completed NCT01812148
36 Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Completed NCT01126346
37 Collecting Tumor Samples From Patients With Gynecological Tumors Completed NCT00897442
38 Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial Completed NCT00904514
39 Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Sur Recruiting NCT01416714
40 Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed Recruiting NCT01617382
41 Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma Recruiting NCT01950572
42 An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Recruiting NCT02754115
43 French National Registry of Rare Peritoneal Surface Malignancies Active, not recruiting NCT02834169
44 EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer Terminated NCT00028782

Search NIH Clinical Center for Malignant Peritoneal Mesothelioma

Genetic Tests for Malignant Peritoneal Mesothelioma

Anatomical Context for Malignant Peritoneal Mesothelioma

MalaCards organs/tissues related to Malignant Peritoneal Mesothelioma:

39
Colon, Lung, Lymph Node, Testis, Liver

Publications for Malignant Peritoneal Mesothelioma

Articles related to Malignant Peritoneal Mesothelioma:

(show top 50) (show all 258)
id Title Authors Year
1
Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization-array. ( 27184482 )
2016
2
Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report. ( 27902597 )
2016
3
Preventing recurrence of diffuse malignant peritoneal mesothelioma. ( 27486718 )
2016
4
Diffuse malignant peritoneal mesothelioma presenting with psammomatous calcification on a cervical smear: A case report. ( 27773157 )
2016
5
CT differentiation of malignant peritoneal mesothelioma and tuberculous peritonitis. ( 26661955 )
2016
6
Computed Tomographic Features of Malignant Peritoneal Mesothelioma. ( 26976999 )
2016
7
A Histomorphologic Grading System That Predicts Overall Survival in Diffuse Malignant Peritoneal Mesothelioma With Epithelioid Subtype. ( 27438989 )
2016
8
Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. ( 27813512 )
2016
9
A Case of Encapsulating Peritoneal Sclerosis Complicated by Malignant Peritoneal Mesothelioma. ( 27628605 )
2016
10
A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma. ( 27187383 )
2016
11
Malignant peritoneal mesothelioma in a patient with intestinal fistula, incisional hernia and abdominal infection: A case report. ( 26998119 )
2016
12
Asbestos content of lung tissue in patients with malignant peritoneal mesothelioma: A study of 42 cases. ( 27281118 )
2016
13
Malignant peritoneal mesothelioma and Crohn disease. ( 27484913 )
2016
14
Management of Malignant Peritoneal Mesothelioma Using Cytoreductive Surgery and Perioperative Chemotherapy. ( 27858561 )
2016
15
Diagnosis and management of patients with malignant peritoneal mesothelioma. ( 26941986 )
2016
16
The Challenge of Defining Treatment Standards for a Rare Disease: Malignant Peritoneal Mesothelioma. ( 27858567 )
2016
17
CT differentiation of diffuse malignant peritoneal mesothelioma and peritoneal carcinomatosis. ( 26645426 )
2016
18
CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. ( 26810896 )
2016
19
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma. ( 27858557 )
2016
20
Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. ( 27472649 )
2016
21
Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma. ( 27428868 )
2016
22
Symptoms, signs and radiologic findings in patients having reoperative surgery for malignant peritoneal mesothelioma. ( 27612411 )
2016
23
Renal cell carcinoma and malignant peritoneal mesothelioma after occupational asbestos exposure: case report. ( 27240221 )
2016
24
Anaplastic lymphoma kinase (ALK) translocation in paediatric malignant peritoneal mesothelioma: a case report of novel ALK-related tumour spectrum. ( 26179668 )
2015
25
Establishment and mutation analysis of a novel malignant peritoneal mesothelioma cell line, TU-MM-1, using whole genome sequencing. ( 26070481 )
2015
26
Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma. ( 26214083 )
2015
27
Diffuse Malignant Peritoneal Mesothelioma Presenting with Psammomatous Calcification on a Cervical Smear. ( 26845517 )
2015
28
Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing. ( 25798586 )
2015
29
The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. ( 26493618 )
2015
30
Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase III+, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray. ( 25777091 )
2015
31
p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer. ( 25972325 )
2015
32
Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. ( 25948791 )
2015
33
Malignant Peritoneal Mesothelioma: Characterization of the Inflammatory Response in the Tumor Microenvironment. ( 26545374 )
2015
34
Malignant peritoneal mesothelioma without asbestos exposure: An ovarian cancer imitator. ( 26076085 )
2015
35
Malignant peritoneal mesothelioma diagnosed by EUS-guided tissue acquisition. ( 26643708 )
2015
36
The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). ( 26572754 )
2015
37
Primary diffuse malignant peritoneal mesothelioma in a striped skunk (Mephitis mephitis). ( 26568187 )
2015
38
Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma. ( 26272336 )
2015
39
Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma. ( 26227745 )
2015
40
Unusual Appearance of Malignant Peritoneal Mesothelioma. ( 25793652 )
2015
41
Malignant Peritoneal Mesothelioma Masquerades as Peritoneal Metastasis on (18)F-FDG PET/CT Scans; a Rare Diagnosis that Should Not Be Missed. ( 26550054 )
2015
42
Malignant Peritoneal Mesothelioma in an Adolescent Male With BAP1 Deletion. ( 25222065 )
2014
43
Pemetrexed Combined with Platinum-based Chemotherapy for Advanced Malignant Peritoneal Mesothelioma: Retrospective Analysis of Six Cases. ( 24403465 )
2014
44
Coexistence of Diffuse Malignant Peritoneal Mesothelioma and Candida norvegensis Peritonitis. ( 25314348 )
2014
45
Malignant peritoneal mesothelioma with lymph node metastasis that originated in the transverse colon. ( 24754918 )
2014
46
Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma. ( 24645844 )
2014
47
Clinical utility of 18F-Fdg positron emission tomography in malignant peritoneal mesothelioma. ( 24727854 )
2014
48
Malignant Peritoneal Mesothelioma With Lower Extremity Metastasis: PET/CT Imaging. ( 24830875 )
2014
49
Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma. ( 24719018 )
2014
50
Anticancer effect of bromelain with and without cisplatin or 5-FU on malignant peritoneal mesothelioma cells. ( 24366282 )
2014

Variations for Malignant Peritoneal Mesothelioma

Expression for Malignant Peritoneal Mesothelioma

Search GEO for disease gene expression data for Malignant Peritoneal Mesothelioma.

Pathways for Malignant Peritoneal Mesothelioma

GO Terms for Malignant Peritoneal Mesothelioma

Biological processes related to Malignant Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein sumoylation GO:0016925 9.16 BIRC5 CDKN2A
2 regulation of protein stability GO:0031647 8.96 CDKN2A NF2
3 negative regulation of cell-matrix adhesion GO:0001953 8.62 CDKN2A NF2

Molecular functions related to Malignant Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 glycoprotein binding GO:0001948 8.62 EGFR VIM

Sources for Malignant Peritoneal Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....